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Summary
Experiments in vitro suggest that although interleukin 5 (IL5) stimulates the late stages ofeosinophil
differentiation, other cytokines are required for the generation of eosinophil progenitor cells.
In this study transgenic mice constitutively expressing the IL-5 gene were established using a
genomic fragment of the 11,5 gene coupled to the dominant control region from the geneencoding
human CD2. Four independent eosinophilic transgenic lines have thus far been established, two
ofwhich with 8 and 49 transgene copies, are described in detail. Thesemice appeared macroscopically
normal apart from splenomegaly. Eosinophils were at least 65- and 265-fold higher in blood
from transgenics, relative to normal littermates, and approximately two- or sevenfold more numerous
relative to blood from mice infected with the helminth Mesocestoides corti. Much more modest
increases in blood neutrophil, lymphocyte, and monocyte numbers were noted in transgenics,
relative to normal littermates (less than threefold). Thus IL-5 in vivo is relatively specific for the
eosinophil lineage. Large numbers ofeosinophils were present in spleen, bone marrow, and peritoneal
exudate, and were highest in the line with the greatest transgene copy number. Eosinophilia
was also noted in histological sections of transgenic lungs, Peyer's patches, mesenteric lymph
nodes, and gut lamina propria but not in other tissues examined. 11,5 was detected in the sera
of transgenics at levels comparable to those seen in sera from parasite-infected animals. IL3 and
granulocyte/macrophage colony-stimulating factor (GM-CSF) were not found. 11,5 mRNA was
detected in transgenic thymus, Peyer's patches, and superficial lymph nodes, but not in heart,
liver, brain, or skeletal muscle or in any tissues from nontransgenics. Bone marrow from transgenic
mice was rich in 11,5-dependent eosinophil precursors. These data indicate that induction of
the IL-5 gene is sufficient for productionofeosinophilia, and that IL-5 can induce the full pathway
of eosinophil differentiation. IL-5 may therefore not be restricted in action to the later stages
of eosinophil differentiation, as suggested by earlier in vitro studies.
T
he generation ofblood leucocytes occurs from a popula-
tion of multipotential stem cells, which undergo a se-
ries ofdifferentiation stepsin which theirmultilineage potential
is progressively restricted. This gives rise to populations of
progenitor cells committed to the different leucocyte lineages.
More is known about the later stages of these pathways since
the discovery of the CSFs, but little is known aboutthe mech-
anisms controlling the production of the progenitor cells.
Eosinophilia is characteristic of allergy and infection by
helminths. One of the intriguing aspects of eosinophilia is
its biological specificity, in which an increase in eosinophils
can occur in the absence of increases in other leucocytes (1,
2). This suggests a lineage specific control mechanism. How-
ever, studies in vitro suggest that the sequential action of
IL1 and IL3 or granulocyte colony-stimulating factor (G-
CSF)t are necessary for progenitor cell production (3-5), and
1 Abbreviations used in thispaper: DCR, dominant control region; G-CSF,
granulocyte colony-stimulating factor.
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that IL5 is responsible only for the differentiation of these
progenitor cells into mature eosinophils (6). As G-CSF stimu-
lates the productionof neutrophils and IL3 is active on many
other lineages, a role for these factors in eosinophilia is para-
doxical.
To define the activity of IL-5 in vivo, transgenic mice have
been produced in which transcription of the IL5 gene is under
the influence of the dominant control region (DCR) of the
gene encoding human CD2 (8) (a T cell surface antigen).
Detailed studies have shown that this region allows the ex-
pression of reporter genes in transgenic mice, which is con-
stitutive, thymocyte and T cell specific, dependent on copy
number, and independent of orientation or insertion site (8, 9).
In this study we compare two transgenic lines of mice,
each expressing different levels of 11,5, with mice infected
with the cestode Mesocestoides corti. We show that constitu-
tive expression ofthe IL5 gene is sufficient to induce lifelong
high-level eosinophilia. The eosinophilia in both transgenic
lines is at least as high as the peak eosinophilia observed in
J. Exp. Med. ® The Rockefeller University Press - 0022-1007/90/11/1425/07 $2.00
Volume 172 November 1990 1425-1431M . corti infection. Despite the wide tissue distribution of eo-
sinophils, the transgenic animals remain physically normal.
Materials and Methods
Production andAnalysis ofTransgenic Mice.
￿
Thehumangenomic
CD2 DCR (8, 9) was obtained as a 5-kb BamHI-XbaI fragment
in the vector polyIII-I. Afterexcision of a 3-kb HindIII fragment,
the10-kb HindIII11,5 genomic fragment (10) wasligated into the
opened vector (Fig. 1) . The 12-kb hybrid gene was excised as a
BamHI fragment andinjected into CBA/Ca oocytes, which were
then transferred to the oviducts of pseudopregnant (CBA/Ca x
C57B6)F, mice using standard techniques (11). Mice were main-
tained by the Institute animal facility. Southern blots were per-
formed with DNAprepared from thetails of 9-30-d-old mice, and
probed with a 650-bp fragment of 11,5 cDNA (12). Densitometnc
analysis of Southern blots was performed using a Chromoscan 3
(Joyce Loebl, Deusseldorf, FRG).
Total RNA was prepared by acid guanidinium thiocyanate-
phenol-chloroform extraction (13), and5-20 ugAample were elec-
trophoresed throughformaldehyde/agarose gels. Northern blot anal-
ysis was performed as described (14) using the IL5 cDNA probe
described above and a riboprobe prepared from actin cDNA (15).
Restriction endonucleases and otherenzymes were obtained from
Boehringer Mannheim (Lewes, UK) or Northumbria Biologicals
Ltd. (Cramlington, UK). Allother reagents were from standard
commercial sources. All techniques not specifically referenced were
performed using standard methods (16).
Cytokine andEosinophil ProgenitorAssays.
￿
11,5 wasobtained from
COS cells transfected with recombinant mouse (rm) IL5 cDNA
(10) . 11,5 wasassayedby theeosinophil differentiation assay (EDA)
(17) . Briefly, sample dilutions were incubatedin microplates with
bone marrow fromM .cortiinfected mice for 5 d. Eosinophil numbers
were determined indirectly by assaying for eosinophil peroxidase.
Absorbance (A492) was read in a plate reader, using cultures in-
cubated in the absence of exogenous 11,5 as blanks.
Eosinophil progenitors were determined indirectly by titrating
bone marrow cells in the presence of a predetermined optimum
concentration of rmIIr5 andbybone marrow responsiveness to IL5.
IIr3/GM-CSF levels were determined by using the factor-
dependent cell line FDCP-2, which detects both of these cyto-
kines (18).
Cytology and Histology.
￿
Slides for differential cell counts were
prepared from single cell suspensions using a cytocentrifuge, or
as standard blood films, fixed with methanol and stained with
Giemsa. 2-5 x 102 cells were countedper slide. Tissues were fixed
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Figure 1.
￿
Map ofhumanCD2(5)andmouseCD2IL5 gene construct
used to generate transgenic mice. Restriction enzyme sites: B, BamHI;
S, Sacl; H, HindIII; X, XbaI. Exons are shown as boxes.
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in neutral buffered formalin, embedded in paraffin and4-6-Am sec-
tions were stained with Congo Red (19) and counterstained with
haematoxylin.
Results
Transgenic Mouse Lines.
￿
Four transgenic offspring were
detected, initially by high eosinophil counts in a smear of
tail blood (counts in excess of 45% at 9 d of age, compared
with a mean of 3% in normal littermates), and later by
Southern analysis of tail DNA. Of 341ivebirths only these
4 animals had increased blood eosinophil counts, and only
these 4 were transgenic by Southern analysis. Independent
transgenic lines have been established from all four of these
founderanimals andaredesignated Tg(0IL5)Cl, 7g(01L5)C2,
Tg(0IL5)C3, and Tg(OIL5)C4, abbreviated Tg5C1, Tg5C2,
Tg5C3, andTg5C4, respectively. Blood eosinophilia in trans-
genic offspring of each line was comparable to that seen in
founders. Data for Tg5C1 and Tg5C2 are presented here.
Southern analysis of Sacl digests indicated they carry ti8 and
49 copies of the transgene, respectively (mean densitometry
curveintegralsof4,626 and 28,272 Ufor Tg5C1 andTg5C2,
respectively, relative to a mean of 591 U for nontransgenic
littermate DNA) .
IL5 TransgeneExpression Is Tissue Restricted.
￿
Northern blot
analysis identified 11,5 mRNA in thethymus, Peyer's patches,
and subcutaneous (pooledinguinal andaxillary) lymphnodes
(Fig. 2a). No IL5 mRNA was detected in liver, heart, brain,
or skeletal muscle tissues from transgenics (not shown), nor
in any tissues from normal littermates. The presence of in-
Figure 2.
￿
Northern analysis of IL5 mRNA in tissues from transgenic
mice (lanes 1-6) andnormal littermates (lanes 7-12). (Lanes 1,7) Thymus;
(lanes 2,8) bone marrow; (lanes 3,9) peyer's patches; (lanes 4,10) spleen;
(lanes 5,11) mesenteric lymph nodes; (lanes 6,12) pooled axillary andin-
guinal lymphnodes. (a) Using an IL5 cDNA probe. (b) Using an actin
RNA probe. mRNA from heart, kidney, brain, muscle, and liver were
negative.Table 1.
￿
Comparative White Blood Cell Counts
Differential counts (%)
WBC, White blood cells; N, neutrophils; Eo, eosinophils; L, lymphocytes; M, monocytes. Values are means ± 1 SD, excepting differential counts
(mean cells/ml and percent ± SD were also calculated, but added little to the analysis and so have been omitted). Spleen weight and serum IL-5
levels (n - 3). Blood cell counts for 9-12-wk-old transgenic mice (n - 5), M. corti-infected mice (n = 2), normal littermates (n = 5) . Normal
mice were counted for each category, but were not significantly different from the normal group presented.
tact mRNA was confirmed using an actin RNA probe (Fig.
2 b). Using three different preparative procedures intact
mRNA was not obtained from transgenic spleen. This is
thought to be due to RNase activity associated with the high
levels of eosinophils in this tissue.
11,5 Levels and Eosinophil Counts in the Blood.
￿
11,5 levels
in sera from transgenic mice were comparable to peak levels
in sera from mice infected with M. corti (Table 1). No IL3
or GM-CSF activity was detected in the same sera.
Tg5C1 and Tg5C2 lines had 65-fold and 265-fold, respec-
tively, the blood eosinophils seen in normal littermates, while
M. corti-infected micewere 35-fold over normal controls (Table
1). Transgenic mice also showed small but significant increases
(up to threefold) in neutrophil, lymphocyte, and monocyte
numbers relative to normal littermates.
Thus, comparing the two transgenic lines, eosinophilia and
IL-5 levels were significantly higher in the line with the highest
transgene copy number. Transgenic mice have been observed
for up to 6 mo and eosinophilia was maintained at relatively
stable levels during this period.
11,5 Production in Transgenic Cell Cultures.
￿
Supernatants
from unstimulated transgenic spleen cell cultures contained
1175, indicating constitutive production, and this was increased
markedly in the presence of ConA. None was detectable in
supernatants from unstimulated normal spleen cells or spleen
cells from miceinfected with M. corti (Table 2) . Surprisingly,
although high levels of mRNA were detected in transgenic
thymus, no 1175 was constitutively produced in culture. How-
ever, when cultured with Con A, very high levels of 11,5
were detected (Table 2) .
In contrast, the levels of IL3/GM-CSF detected in trans-
genic spleen and thymus cell cultures were similar to normal
spleen cultures, and negligible relative to supernatants from
the IL3-producing cell line WEHI-3D.
Tissue Distribution of Eosinophils.
￿
Total and differential
counts on single cell suspensions prepared from various tissues
revealed major eosinophil localisation in the spleen, bone
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Blood cells/ml (x 10-s)
marrow, and peritoneal exudate (Fig. 3) . Both the bone
marrow and the spleen contained many morphologically im-
mature forms, indicating active eosinophil haemopoiesis in
both organs. Transgenics had enlarged spleens (Table 1), with
a high proportion of eosinophils relative to nontransgenic
littermates. Both transgenic lines had a high percentage of
eosinophils in the peritoneal exudate, although the total
number was lower than from mice infected with M. corti.
For example, the approximate total numbers of peritoneal
eosinophils for Tg5C1, Tg5C2, and parasitized mice were 2
x 106, 5 x 106, and 20 x 106, respectively. Eosinophils
represented 1% ofthymocytes and 3% ofmesenteric lymph
node cells recovered from transgenics. Although relatively
low compared with the spleen these are significantly higher
than normal littermates, where eosinophils were virtually un-
detectable.
Values are means ± 1 SD of50% endpoints of replicate culture superna-
tants in each assay. WEHI-3D-conditioned medium gave 5,744 U in
the IL-3/GM-CSF assay.
Mice
(gene copy no.) Spleen weight Serum IL-5
Total
WBC N Eo L M
mg U
Tg5C1 (8) 205 ± 3 39 ± 11 305 ± 14 35 (12) 130 (44) 130 (44) 5 (2)
Tg5C2 (49) 675 ± 166 73 ± 27 786 ± 16 60 (8) 530 (68) 210 (27) 9 (2)
M. corti 450 ± 35 55 ± 13 250 ± 35 85 (34) 70 (28) 33 (33) 13 (5)
Normal 58 ± 2 <1 119 ± 8 18 (16) 2 (2) 98 (82) 2 (2)
Table 2 . Cytokine Production in Spleen and Thymocyte Cultures
Cultures Control
IL-3/GM-CSF
Con A Control
IL-5
Con A
Spleen
Tg5C1 12 ± 1 26 ± 1 37 ± 6 339 ± 53
M. corti 3 ± 2 10 ± 1 <1 8 ± 7
Normal 14 ± 4 5 ± 3 <1 16 ± 15
Thymus
Tg5C1 <1 6 ± 1 <1 241 ± 92
Normal <1 2 ± 2 <1 <1Figure 3.
￿
Tissue distribution of eosinophils in transgenic lines Tg5C1
and Tg5C2, M. corti-infected BALB/c mice (Mn) and nontransgenic lit-
termates (Normal). Representative data from one experiment with animals
killed at 8 wk of age. PE, peritoneal exudate; BM, bonemarrow; Sp, spleen.
Histological sections showed that most of the eosinophils
in the spleen were located in the red pulp with very few in
the white pulp area (Fig. 4, a and b; transgenic and normal,
respectively). It was also noted that the lungs of transgenic
but not of normal animals were heavily infiltrated with eo-
sinophils (Fig. 4, c and d, respectively). Small but significant
numbers of eosinophils were also observed in sections ofmesen-
tericlymph nodes, peyer's patches, and lamina propria of the
small intestine from transgenics. None of the other tissue
sections examined (heart, liver, skeletal muscle, or brain)
showed increased numbers of eosinophils.
IL5-responsive Eosinophil Precursors in Bone Marrow.
￿
Lim-
iting dilution culture ofbone marrow in the presence ofIL5
indicated that cells from transgenics had >10-fold higher ca-
pacity to produce eosinophils than normal littermates (Fig.
5). The capacity of transgenic marrow was also higher than
that of bone marrow from mice infected with M. corti.
Another indirect measure of eosinophil progenitors is the
sensitivity of the bone marrow to detect IL5. This is illus-
trated in Fig. 6 where the bone marrow can be ranked in
order of increasing sensitivity: normal, M. corti, Tg5C1 and
Tg5C2. Although not obvious in these data thebone marrow
from M. corti-infected mice is several orders of magnitude
more sensitive than normal bone marrow (1) .
Discussion
We report here the generation of four founder mice car-
rying transgenes for the cytokine IL5. All four mice were
eosinophilic, and independent lines have been established from
each. Two of these lines carrying 8 or 49 copies of the trans-
gene are reported here. The transgene was constructed by
ligating a 2-kb fragment of humangenomic DNA containing
the DCR of the human CD2 gene (8) to a 10-kb DNA frag-
ment containing the mouse IL5 gene (10). The DCR was
placed 5' of the IL -5 gene. The murine fragment included
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flanking sequences of -4 kb upstream from the 11,5 cap site,
and 1.3 kb downstream from the polyadenylation attachment
site of the 11,5 gene. These flanking regions are likely to con-
tain many of the elements controlling the expression of the
IL -5 gene, including the IL5 promoter. Thus, while tran-
scription is occurring from the IL5 promoter, the CD2 DCR
is acting to override other normal transcriptional controls
on the IL5 gene, allowing constitutive secretion of 11,5. The
level ofconstitutive transgene expression has not been estab-
lished, but may be lower than the induced expression of the
endogenous gene. For example, the levels of IL5 detected
in transgenic sera are not as high as might be anticipated from
the number of transgenes, when compared with the levels
produced following expression by the single gene in normal
mice infected with M. corti. It is possible that the transgenes
retain the capacity to show normal inducible expression in
response to activation. Some evidence for this is seen in the
high levels of 11,5 produced by transgenic lymphoid organs
after the addition of Con A.
Although the thymus of Tg5C1 contained high levels of
IL5 mRNA no 11,5 was secreted except afteraddition ofCon
A. This failure to secrete IL5 constitutively in culture is puz-
zling, and it is not clear whether it represents a real inability
to secrete, or simply a failure to secrete in vitro. Spleen cells
secreted IL5 constitutively in vitro and this was further in-
creased after addition of ConA. In contrast little or no IL-3
or GMCSF was detected from either cell type.
The level of expression ofother CD2 DCR transgene con-
structs is dependent upon transgene copy number and is T
cell-specific (8, 9). Similarly, serum IL5 levels and tissue eo-
sinophilia were higher in the IL5 transgenic line with the
greatest copy number (Tg5C2). Further, IL5 mRNA tran-
scription patterns are consistent with transgene expression
restricted to lymphoid tissues.
Both transgenic lineshad profound, continuous eosinophilia
in the blood, lymphoid, and hematopoietic tissues. Exten-
sive eosinophilic infiltration of the lungs and intestinal lamina
propria was also noted. Bone marrow from transgenics was
rich in eosinophil progenitors as indicated by the number of
immature cells observed, and by increased responsiveness to
116. Transgenics were compared with miceinfected with the
helminth M. corti, a pathogen known to induce high levels
of eosinophilia and elevated serum IL5 (1). In most tissues
the numbers ofeosinophils were higher in the transgenic lines
compared with parasite-infected animals, although it must
be remembered that eosinophilia in the parasitized mice is
only transient and the animals included in this study may
not have been at peak eosinophilia (1).
These transgenic mice raise some interesting points about
the control of eosinophilia. Since its first characterization,
studies in vitro have suggested that 11,5 is a late-acting factor
in eosinophil differentiation (3-7) . Eosinophils were produced
only transiently in long-term bone marrow cultures stimu-
lated with exogenous IL5, suggesting that at least in these
systems the progenitor cells were not being produced from
stem cells. In addition, bone marrow from eosinophilic
parasite-infected mice gives rise to many more eosinophils
than bone marrow from normal mice, indicating that theparasitic infection stimulates the production ofprogenitors.
This suggests that othercytokines may beinducing the pro-
genitors, and indeed it has been shown that ILl, IL3, and
possibly G-CSF and GM-CSF are involved in this process (4,
6). Similarly, in studies with human bone marrow, both IL3
and GM-CSF but not IL5 induced eosinophil precursors, as-
sayed as IL5-responsive colony-forming cells (5, 7) . How-
ever, the transgenics show that IL5 expression is sufficient
to induce eosinophilia, which suggests that IL5 in vivo is
able to control the production of eosinophil progenitors. Al-
though a role for other cytokines in this process cannot be
ruled out, they must be either constitutively expressed or
their expression is induced by 11,5. It should be noted that
no significant production of IL3 or GM-CSF was detected,
and so there is no apparent induction of these cytokines in
the transgenic mice.
It has recently been shown that parasite-induced eosinophilia
can be blocked by the in vivo administrationofanti-M5 mAbs
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Figure 4.
￿
Histological sections of
spleens and lungs from the Tg5C1 line
(a, c, respectively) and a nontransgenic
littermate (b, d, respectively), showing
extensive eosinophilia in the trans-
genic tissue relative to nonttansgenics.
Eosinophil granules stain red-orange.
(20, 21). Thus, whileboth IL3 and GM-CSF induce eosino-
phil production in vitro, these experiments in vivo suggest
that IIr3 and GM-CSF do not operate in the development
of eosinophilia in parasitic infections. Together with these
results, the present study of IIr5 transgenic mice points to
a major role for IL5 in thecontrol ofeosinophilia. This pro-
vides an explanation for the biological specificity of eosinophilia
(1, 2), as it appears that cytokines such as 11,3 and GM-CSF
are not primarily involved in its induction. In both trans-
genic lines there was a small but significant increase in blood
neutrophils and monocytes. It is not clear whether this
represents a direct effect ofIL5 on these lineages, or whether
itis secondary to the largeturnover ofeosinophils. It should
be noted that studies in vitro showed a decrease in neutro-
phil numbers in bone marrow cultures containing IIr5 (3).
11,5 also has a well-characterized activity on B cells, with
more recent reports of activities on T cells (reviewed in refer-
ence 22). Although there were also increases in lymphocyte2.5 1
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Figure 5.
￿
Eosinophils in bone marrow cultures after 5 d, detected by
assay for eosinophil peroxidase (A49z). Serial titration of bone marrow cells
in thepresence ofaconstant amount ofrmII'5. Dataindicaterelative produc-
tion ofeosinophils in bone marrow from different sources. Normal mice
("), M. cord-infectedmice (/), Tg5C1mice (A), andTg5C2mice (0).
Data are means ± 1 SD of duplicate cultures.
numbers in transgenics relative to nontransgenic controls, the
changeswere marginal compared with the magnitudeof the
eosinophil response. Preliminary flow cytometric analysis has
notrevealed anymajor selective increasesin Tor Bcell subsets.
Further experiments arebeingcarried outto clarifytheseissues.
In thedesign ofthesetransgenic animalswe havebeen aware
of the T cell dependence of eosinophilia, and the fact that
IM is normally a T cell product (23). The use of the CD2
DCR should ensure constitutive expression by T cells, and
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